DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Bavituximab is an investigational drug.
There have been 25 clinical trials for Bavituximab. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Breast Neoplasms. The leading clinical trial sponsors are Peregrine Pharmaceuticals, University of Texas Southwestern Medical Center, and Merck Sharp & Dohme Corp.
There are twenty-eight US patents protecting this investigational drug and seven hundred and thirty-nine international patents.
Recent Clinical Trials for Bavituximab
|An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients||Merck Sharp & Dohme Corp.||Phase 2|
|An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients||Oncologie Inc.||Phase 2|
|Randomized Phase II Study of Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide Progression||Genzyme, a Sanofi Company||Phase 2|
Top disease conditions for Bavituximab
Top clinical trial sponsors for Bavituximab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Bavituximab||See Pricing||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||See Pricing|
|Bavituximab||See Pricing||.beta.-glucan methods and compositions that affect the tumor microenvironment||BIOTHERA, INC. (Eagan, MN)||See Pricing|
|Bavituximab||See Pricing||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||See Pricing|
|Bavituximab||See Pricing||Method of treating pancreatic cancer||ChemoCentryx, Inc. (Mountain View, CA)||See Pricing|
|Bavituximab||See Pricing||Compositions and methods for detecting protease activity in biological systems||CytomX Therapeutics, Inc. (South San Francisco, CA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Bavituximab||European Patent Office||2954056||2033-02-08||See Pricing|
|Bavituximab||Hong Kong||1218930||2033-02-08||See Pricing|
|Bavituximab||World Intellectual Property Organization (WIPO)||2014124326||2033-02-08||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|